To access this element change to forms mode OFF
Grant Award View - GA22382
Broadening the Efficacy of Cancer Immunotherapies
GA ID:
GA22382
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
16-Jul-2018
Publish Date:
2-Oct-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2022
Value (AUD):
$483,404.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Career Development Fellowship
Grant Activity:
Broadening the Efficacy of Cancer Immunotherapies
Purpose:
Over the past 5 years, antibodies targeting immunomodulatory receptors such as Ipilimumab, Nivolumab/Pembrolizumab have been revolutionary in causing long term tumor regression and disease free survival in advanced cancers. My vision is to increase the proportion of cancer patients that will respond to immunotherapy by exploring novel pathways and combinations and optimizing their scheduling and assessing their safety in mouse models to allow their rapid translation into the clinic.
GO ID:
GO Title:
NHMRC Career Development Fellowships for funding commencing in 2019
Internal Reference ID:
GNT1159655
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
QIMR Berghofer Medical Research Institute
Recipient ABN:
31 411 813 344
Grant Recipient Location
Suburb:
Herston
Town/City:
Herston
Postcode:
4006
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
QLD
Postcode:
Country:
AUSTRALIA